Abstract
Background: Remdesivir, a drug in use for Ebola it is already tested in clinical trials phase III.
Objective: To evaluate any other possible related structures with similar properties that could be used in clinical trials for COVID-19.
Methods: Molecular docking studies, DFT studies, ADMET studies.
Result: Saquinavir is a chemical structure with similar and even a better chemical activity that drugs that entered clinical trials for COVID-19.
Conclusion: Saquinavir should be entered the clinical trials for the treatment of the COVID-19 disease, as it has shown excellent binding affinities to SARS Cov-2 RNA depended polymerase and forms stable complexes with the protein and could possible inhibited its action.
Keywords: COVID-19, remdesivir, molecular docking, DFT studies, toxicity studies, SARS Cov-2 RNA depended polymerase, saquinavir.
Letters in Drug Design & Discovery
Title:Molecular Docking, DFT Studies and ADMET Simulations for Evaluating Already Approved FDA Drugs as Inhibitors for SARS-Cov-2 RNADependent Polymerase
Volume: 18 Issue: 7
Author(s): Manos C. Vlasiou*, Kyriakos I. Ioannou and Kyriaki S. Pafiti
Affiliation:
- Department of Life and Health Sciences, University of Nicosia, Nicosia 2417,Cyprus
Keywords: COVID-19, remdesivir, molecular docking, DFT studies, toxicity studies, SARS Cov-2 RNA depended polymerase, saquinavir.
Abstract:
Background: Remdesivir, a drug in use for Ebola it is already tested in clinical trials phase III.
Objective: To evaluate any other possible related structures with similar properties that could be used in clinical trials for COVID-19.
Methods: Molecular docking studies, DFT studies, ADMET studies.
Result: Saquinavir is a chemical structure with similar and even a better chemical activity that drugs that entered clinical trials for COVID-19.
Conclusion: Saquinavir should be entered the clinical trials for the treatment of the COVID-19 disease, as it has shown excellent binding affinities to SARS Cov-2 RNA depended polymerase and forms stable complexes with the protein and could possible inhibited its action.
Export Options
About this article
Cite this article as:
Vlasiou C. Manos *, Ioannou I. Kyriakos and Pafiti S. Kyriaki , Molecular Docking, DFT Studies and ADMET Simulations for Evaluating Already Approved FDA Drugs as Inhibitors for SARS-Cov-2 RNADependent Polymerase, Letters in Drug Design & Discovery 2021; 18 (7) . https://dx.doi.org/10.2174/1570180817999201211192513
DOI https://dx.doi.org/10.2174/1570180817999201211192513 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function
Current HIV Research The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design A New Battlefield Towards Global Health in 21<sup>st</sup> Century: Clinical Research Networks
Applied Clinical Research, Clinical Trials and Regulatory Affairs Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
CNS & Neurological Disorders - Drug Targets Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Suppression of Virulence of Porphyromonas gingivalis by Potent Inhibitors Specific for Gingipains
Current Protein & Peptide Science Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Periodontal Bacteria Aggravate Chronic Renal Failure Induced by Subtotal Nephrectomy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design